{"transactions":[{"id":2991118,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-05T08:56:59.000Z","date":"2020-11-04","kind":"sale","acquired":false,"shares":2268750,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 4, 2020, Topspin Biotech Fund II, L.P. distributed the 2,268,750 shares owned by it as follows: (1) 2,155,607 shares were distributed in-kind to its limited partners; and (2) 113,143 were distributed at the direction of LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., as follows: (a) 56,572 were distributed to Leo A. Guthart, the managing member of LG Management, LLC; and (b) an aggregate of 56,571 were distributed to two third-parties. The 113,143 shares distributed at the direction of LG Management, LLC were shares to which it was entitled in its capacity as general partner of Topspin Biotech Fund II, L.P."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of (1) 1,043,874 shares held of record by Topspin Fund, LP.; and (2) 56,572 shares owned by Leo A Guthart, individually. Each of Topspin Fund, LP and Leo A. Guthart disclaims beneficial ownership of the shares held of recod by the other."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On November 4, 2020, Topspin Biotech Fund II, L.P. distributed the 2,268,750 shares owned by it as follows: (1) 2,155,607 shares were distributed in-kind to its limited partners; and (2) 113,143 were distributed at the direction of LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., as follows: (a) 56,572 were distributed to Leo A. Guthart, the managing member of LG Management, LLC; and (b) an aggregate of 56,571 were distributed to two third-parties. The 113,143 shares distributed at the direction of LG Management, LLC were shares to which it was entitled in its capacity as general partner of Topspin Biotech Fund II, L.P."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"1,043,874 of such shares are held directly by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of (1) 1,043,874 shares held of record by Topspin Fund, LP.; and (2) 56,572 shares owned by Leo A Guthart, individually. Each of Topspin Fund, LP and Leo A. Guthart disclaims beneficial ownership of the shares held of recod by the other."}],"balance_after":1100446,"source":{"system":"sec-edgar","filing":"0001104659-20-121613","document":"tm2035065-2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000110465920121613/tm2035065-2_4.xml","form_type":"4"}},{"id":3130706,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T12:21:53.000Z","date":"2020-05-26","kind":"sale","acquired":false,"shares":2056666,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 26, 2020, Topspin Biotech Fund II, L.P. distributed the 1,641,666 shares owned by it as follows: (1) 1,559,990 shares were distributed in-kind to its limited partners; and (2) 81,676 were distributed at the direction of LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., as follows: (a) 40,538 were distributed to Leo A. Guthart, the managing member of LG Management, LLC; and (b) an aggregate of 41,138 were distributed to two third-parties. The 81,676 shares distributed at the direction of LG Management, LLC were shares to which it was entitled in its capacity as general partner of Topspin Biotech Fund II, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On May 26, 2020, Topspin Fund, L.P. distributed 415,000 shares owned by it to one of its limited partners."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of (1) 518,705 shares held of record by Topspin Fund, LP.; and (2) 40,538 shares owned by Leo A Guthart, individually. Each of Topspin Fund, LP and Leo A. Guthart disclaims beneficial ownership of the shares held of recod by the other."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On May 26, 2020, Topspin Biotech Fund II, L.P. distributed the 1,641,666 shares owned by it as follows: (1) 1,559,990 shares were distributed in-kind to its limited partners; and (2) 81,676 were distributed at the direction of LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., as follows: (a) 40,538 were distributed to Leo A. Guthart, the managing member of LG Management, LLC; and (b) an aggregate of 41,138 were distributed to two third-parties. The 81,676 shares distributed at the direction of LG Management, LLC were shares to which it was entitled in its capacity as general partner of Topspin Biotech Fund II, L.P."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On May 26, 2020, Topspin Fund, L.P. distributed 415,000 shares owned by it to one of its limited partners."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"518,705 of such shares are held directly by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of (1) 518,705 shares held of record by Topspin Fund, LP.; and (2) 40,538 shares owned by Leo A Guthart, individually. Each of Topspin Fund, LP and Leo A. Guthart disclaims beneficial ownership of the shares held of recod by the other."}],"balance_after":559243,"source":{"system":"sec-edgar","filing":"0001104659-20-067505","document":"tm2021084-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000110465920067505/tm2021084-1_4.xml","form_type":"4"}},{"id":3168408,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-04-28T17:11:56.000Z","date":"2020-04-28","kind":"exercise","acquired":false,"shares":2268750,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Topspin Biotech Fund II, L.P. LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2268750},"source":{"system":"sec-edgar","filing":"0001209191-20-025989","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000120919120025989/doc4.xml","form_type":"4"}},{"id":3168407,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-04-28T17:11:56.000Z","date":"2020-04-28","kind":"exercise","acquired":false,"shares":314815,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Topspin Fund, L.P. LG Management, LLC, the general partner of Topspin Fund, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":314815},"source":{"system":"sec-edgar","filing":"0001209191-20-025989","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000120919120025989/doc4.xml","form_type":"4"}},{"id":3168406,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-04-28T17:11:56.000Z","date":"2020-04-28","kind":"exercise","acquired":false,"shares":497809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Topspin Fund, L.P. LG Management, LLC, the general partner of Topspin Fund, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":497809},"source":{"system":"sec-edgar","filing":"0001209191-20-025989","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000120919120025989/doc4.xml","form_type":"4"}},{"id":3168405,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-04-28T17:11:56.000Z","date":"2020-04-28","kind":"exercise","acquired":false,"shares":231250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Topspin Fund, L.P. LG Management, LLC, the general partner of Topspin Fund, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":231250},"source":{"system":"sec-edgar","filing":"0001209191-20-025989","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000120919120025989/doc4.xml","form_type":"4"}},{"id":3168404,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-28T17:11:56.000Z","date":"2020-04-28","kind":"exercise","acquired":true,"shares":2268750,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Topspin Biotech Fund II, L.P. LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":2268750,"source":{"system":"sec-edgar","filing":"0001209191-20-025989","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000120919120025989/doc4.xml","form_type":"4"}},{"id":3168403,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-28T17:11:56.000Z","date":"2020-04-28","kind":"exercise","acquired":true,"shares":314815,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Topspin Fund, L.P. LG Management, LLC, the general partner of Topspin Fund, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":1043874,"source":{"system":"sec-edgar","filing":"0001209191-20-025989","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000120919120025989/doc4.xml","form_type":"4"}},{"id":3168402,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-28T17:11:56.000Z","date":"2020-04-28","kind":"exercise","acquired":true,"shares":497809,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Topspin Fund, L.P. LG Management, LLC, the general partner of Topspin Fund, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":729059,"source":{"system":"sec-edgar","filing":"0001209191-20-025989","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000120919120025989/doc4.xml","form_type":"4"}},{"id":3168401,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-28T17:11:56.000Z","date":"2020-04-28","kind":"exercise","acquired":true,"shares":231250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Topspin Fund, L.P. LG Management, LLC, the general partner of Topspin Fund, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":231250,"source":{"system":"sec-edgar","filing":"0001209191-20-025989","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000120919120025989/doc4.xml","form_type":"4"}},{"id":3369973,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2019-11-15T14:52:02.000Z","date":"2019-11-04","kind":"exercise","acquired":false,"shares":155201,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above."}],"balance_after":0,"derivative":{"exercise_date":"2019-11-04","underlying":"Common Stock","underlying_shares":155201},"source":{"system":"sec-edgar","filing":"0001104659-19-064691","document":"tv532611_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000110465919064691/tv532611_4.xml","form_type":"4"}},{"id":3369972,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-11-15T14:52:02.000Z","date":"2019-11-04","kind":"exercise","acquired":false,"shares":363504,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above."}],"balance_after":0,"derivative":{"exercise_date":"2019-11-04","underlying":"Common Stock","underlying_shares":363504},"source":{"system":"sec-edgar","filing":"0001104659-19-064691","document":"tv532611_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000110465919064691/tv532611_4.xml","form_type":"4"}},{"id":3369971,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-11-15T14:52:02.000Z","date":"2019-11-04","kind":"exercise","acquired":false,"shares":1641666,"ownership":{"direct":false,"nature":"See footnotes 2, 3 and 4"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above."}],"balance_after":0,"derivative":{"exercise_date":"2019-11-04","underlying":"Common Stock","underlying_shares":1641666},"source":{"system":"sec-edgar","filing":"0001104659-19-064691","document":"tv532611_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000110465919064691/tv532611_4.xml","form_type":"4"}},{"id":3369970,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-15T14:52:02.000Z","date":"2019-11-04","kind":"purchase","acquired":true,"shares":415000,"price":12,"value":4980000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of (1) 1,641,666 shares held of record by Topspin Biotech Fund II, LP; and (ii) 933,705 shares held of record by Topspin Fund, LP. Each of Topspin Biotech Fund II, LP and Topspin Fund, LP disclaims beneficial ownership of the shares held of record by the other."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"1,641,666 of such shares are held directly by Topspin Biotech Fund II, L.P. LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"933,705 of such shares are held directly by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of (1) 1,641,666 shares held of record by Topspin Biotech Fund II, LP; and (ii) 933,705 shares held of record by Topspin Fund, LP. Each of Topspin Biotech Fund II, LP and Topspin Fund, LP disclaims beneficial ownership of the shares held of record by the other."}],"balance_after":2575371,"source":{"system":"sec-edgar","filing":"0001104659-19-064691","document":"tv532611_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000110465919064691/tv532611_4.xml","form_type":"4"}},{"id":3862887,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E-1 Preferred Stock","published_at":"2018-07-23T20:07:04.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":260114,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MSSB C/F Leo A. Guthart"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are held directly by individual retirement accounts in the name of Leo A. Guthart and as a result Leo A Guthart may be deemed to be the beneficial owner of such shares. Leo A. Guthart disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest in such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23627},"source":{"system":"sec-edgar","filing":"0000899243-18-020453","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000089924318020453/doc4.xml","form_type":"4"}},{"id":3862886,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Preferred Stock","published_at":"2018-07-23T20:07:04.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":266667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MSSB C/F Leo A. Guthart"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are held directly by individual retirement accounts in the name of Leo A. Guthart and as a result Leo A Guthart may be deemed to be the beneficial owner of such shares. Leo A. Guthart disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest in such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":31143},"source":{"system":"sec-edgar","filing":"0000899243-18-020453","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000089924318020453/doc4.xml","form_type":"4"}},{"id":3862885,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E-1 Preferred Stock","published_at":"2018-07-23T20:07:04.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":6069332,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Funds"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are directly held by Topspin Biotech Fund L.P. LG Management, LLC, the general partner of Topspin Biotech Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":551306},"source":{"system":"sec-edgar","filing":"0000899243-18-020453","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000089924318020453/doc4.xml","form_type":"4"}},{"id":3862884,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Preferred Stock","published_at":"2018-07-23T20:07:04.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":6222222,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Funds"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are directly held by Topspin Biotech Fund L.P. LG Management, LLC, the general partner of Topspin Biotech Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":726678},"source":{"system":"sec-edgar","filing":"0000899243-18-020453","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000089924318020453/doc4.xml","form_type":"4"}},{"id":3862883,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F Preferred Stock","published_at":"2018-07-23T20:07:04.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":4500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":408758},"source":{"system":"sec-edgar","filing":"0000899243-18-020453","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000089924318020453/doc4.xml","form_type":"4"}},{"id":3862882,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E-1 Preferred Stock","published_at":"2018-07-23T20:07:04.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":173408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15750},"source":{"system":"sec-edgar","filing":"0000899243-18-020453","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000089924318020453/doc4.xml","form_type":"4"}},{"id":3862881,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Preferred Stock","published_at":"2018-07-23T20:07:04.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":177777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":20762},"source":{"system":"sec-edgar","filing":"0000899243-18-020453","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000089924318020453/doc4.xml","form_type":"4"}},{"id":3862880,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-23T20:07:04.000Z","date":"2018-07-23","kind":"exercise","acquired":true,"shares":54770,"ownership":{"direct":false,"nature":"By MSSB C/F Leo A. Guthart"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are held directly by individual retirement accounts in the name of Leo A. Guthart and as a result Leo A Guthart may be deemed to be the beneficial owner of such shares. Leo A. Guthart disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest in such shares."}],"balance_after":54770,"source":{"system":"sec-edgar","filing":"0000899243-18-020453","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000089924318020453/doc4.xml","form_type":"4"}},{"id":3862879,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-23T20:07:04.000Z","date":"2018-07-23","kind":"exercise","acquired":true,"shares":1277984,"ownership":{"direct":false,"nature":"By Funds"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are directly held by Topspin Biotech Fund L.P. LG Management, LLC, the general partner of Topspin Biotech Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":1277984,"source":{"system":"sec-edgar","filing":"0000899243-18-020453","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000089924318020453/doc4.xml","form_type":"4"}},{"id":3862878,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":145515,"kind":"organization","name":"Topspin Fund L.P.","position":1,"cik":"0001615782","reported_name":"Topspin Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145516,"kind":"organization","name":"Topspin Biotech Fund II, L.P.","position":2,"cik":"0001745827","reported_name":"Topspin Biotech Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145517,"kind":"organization","name":"LG Management, LLC","position":3,"cik":"0001685869","reported_name":"LG Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145518,"kind":"person","name":"GUTHART LEO","position":4,"cik":"0001200183","reported_name":"GUTHART LEO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-23T20:07:04.000Z","date":"2018-07-23","kind":"exercise","acquired":true,"shares":445270,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares."}],"balance_after":445270,"source":{"system":"sec-edgar","filing":"0000899243-18-020453","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685869/000089924318020453/doc4.xml","form_type":"4"}}]}